Published in final edited form as:

Curr Pharm Biotechnol. 2015 ; 16(7): 621–629.

Drug Delivery Systems for Wound Healing

Noah R. Johnson^{1,2} and Yadong Wang^{1,2,3,4,5,*}

¹Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15219, USA

²McGowan Institute for Regenerative Medicine, Pittsburgh, PA 15219, USA

³Department of Chemical and Petroleum Engineering, University of Pittsburgh, Pittsburgh, PA 15219, USA

⁴Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15219, USA

⁵Department of Mechanical Engineering and Materials Science, University of Pittsburgh, Pittsburgh, PA 15219, USA

Abstract

Protein, gene, and small molecule therapies hold great potential for facilitating comprehensive tissue repair and regeneration. However, their clinical value will rely on effective delivery systems which maximize their therapeutic benefit. Significant advances have been made in recent years towards biomaterial delivery systems to satisfy this clinical need. Here we summarize the most outstanding advances in drug delivery technology for cutaneous wound healing.

Keywords

Biomaterial; coacervate; controlled release; drug delivery; hydrogel; microparticle; scaffold; wound healing

INTRODUCTION

Wound healing is a highly coordinated process which relies on precise spatiotemporal presentation of signals to succeed. Significant progress has been made in identifying these signaling molecules and their mechanisms of action in both healthy and diseased states [1–5]. Consequently, there has also been great interest in applying these signals therapeutically to accelerate healing, or enable healing which will otherwise never occur naturally. The current limitation for therapies involving proteins, genes, and small molecule drugs has been a delivery system which can effectively enable their full therapeutic benefit. Namely, a delivery system in the context of wound healing should do the following for its cargo: 1) Maintain its bioactivity through protection from proteolysis in the wound bed, 2) Localize its bioavailability by preventing rapid dilution in wound fluid and systemic uptake and

*Address correspondence to this author at the 320 Benedum Hall, 3700 O'Hara St, Pittsburgh, PA 15261 USA; Tel: 1-(412) 624-7196; Fax: 1-(412) 524-3699; yaw20@pitt.edu.

CONFLICT OF INTEREST

The author(s) confirm that this article content has no conflict of interest.

distribution, 3) Facilitate its release or presentation within the wound at a physiologically relevant rate and duration. If these goals are achieved, a successful delivery system will also minimize the dosage and application frequency necessary for efficacy.

Here we aim to highlight recent advances in delivery systems for wound healing applications. As the topic has been thoroughly reviewed several times in the past [6–8], we place particular emphasis on those systems developed in recent years (>75% of references have been reported since 2008). We identify 5 vehicle types which include hydrogels, scaffolds, particles, complexes, and coacervates (Fig. 1) and provide numerous examples to discuss their advantages and potential drawbacks. In effort to provide adequate depth, we limit our scope to biomaterial-based delivery systems for proteins and small molecule drugs with demonstrated efficacy for skin wound healing but not bone, muscle, or other epithelial defects such as those of the cornea. We include several systems for sustained release of genes and plasmids but not trans-membrane vehicles for gene transfer as these have a separate set of criteria and limitations [9, 10]. We also exclude biomaterial scaffolds for delivering cells in the classical tissue engineering paradigm, as well as therapies which have already received FDA approval as these have been reviewed extensively [11–13].

HYDROGELS

Hydrogels are one of the most highly utilized delivery vehicles. They are versatile, able to form from nearly any water-soluble polymer. They also feature a number of tunable parameters such as porosity, swelling ratio, and cross-link density to offer some control over release rate. A final advantage is that to an extent, they may mimic the mechanical properties of the granulation tissue and maintain a moist wound environment [6, 14].

Hydrogels are often formed from naturally occurring materials because of their abundance and good biocompatibility. Chitosan is one such natural hydrogel commonly employed in controlled release vehicles, appealing in part for its inherent benefits in the wound healing process [15]. Chitosan membranes have been used to cover a wound and slowly release antibiotics such as silver sulfadiazine as they swell. These membranes can be single layer [16] or bilayer [17], and their release may be tuned by variable addition of a second component such as alginate [18]. Chitosan sponges have also been described for controlled release of several different antibiotics to prevent microorganism infection [19–22] and have been evaluated *in vivo* [23]. Chitosan hydrogels delivering fibroblast growth factor-2 (FGF-2) have proved successful in extending the protein's bioactivity and improving wound repair in diabetic mice [24, 25]. Another major advantage of hydrogels for wound healing applications is that they may be designed to polymerize on demand and thereby conform to the defect space. For example, chitosan hydro-gels, designed to polymerize by enzyme-catalyzed cross-linking as injected into the defect, and were used to delivery rutin, a flavonol glycoside with healing properties [26]. Similarly, photo-cross-linkable chitosan hydrogels have been developed to polymerize in the wound after 20s of exposure to UV light [27].

Fibrin is another naturally derived material often used in wound healing applications, owed to its involvement in wound hemostasis [28]. In one intriguing study, fibrin was tethered to plasmid hypoxia-inducible factor-1 α (HIF-1 α) via a peptide linker which resulted in a

robust angiogenic response within the wound bed [29]. In another case, fibrin was employed as a carrier for adenovirus-mediated endothelial nitric oxide synthase (eNOS) gene transfer which up-regulated wound nitric oxide (NO) levels [30]. Interestingly, the release mechanism of adenovirus in this approach is through fibrinolysis, initiated by local cells which are then promptly transfected [31]. This therapy was then advanced to co-deliver plasmid eNOS with the Rab18 gene which regulates inflammatory cytokine and proteolytic enzyme secretion. This unique approach targeting angiogenesis, inflammation, and proteolysis was tested in a hyperglycemic ulcer model using rabbits and led to numerous positive healing measures [32]. Growth factors have also been delivered using fibrin gel. For example, delivered keratinocyte growth factor (KGF) successfully stimulated healing in a skin-grafted humanized mouse model [33]. Likewise, fibroblast growth factor-1 (FGF-1) delivered by a modified fibrin gel resulted in angiogenesis and may potentially be used to treat chronic wounds [34, 35].

A common strategy to facilitate delivery vehicle loading is to conjugate heparin or other glycosaminoglycans with affinity to growth factors, cytokines and morphogens [36]. Heparin-conjugated fibrin was developed to sequester heparin-binding factors from platelet-rich plasma (PRP) including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and FGF-2, and provide their sustained release. When applied to full-thickness mouse wounds, healing measures such as epithelialization and angiogenesis were enhanced compared with PRP alone or unmodified fibrin [37]. These results demonstrate the importance of protein loading and stabilization in development of delivery systems, particularly those for proteins with short half-lives. Drawing too from this concept, synthetic extracellular matrix (ECM) films were formed by cross-linking chondroitin sulfate and heparan sulfate and loaded with FGF-2. When applied to large excisional wounds on genetically diabetic *db/db* mice, the films induced dramatically faster wound closure by mimicking native ECM function in the wound bed [38].

In another utilization of natural materials, gelatinhyaluronate sponges were loaded with epidermal growth factor (EGF) and silver sulfadiazine. In rat excisional wounds, the two molecules acted synergistically to significantly reduce inflammation and increase cell proliferation in the early stages of healing [39]. A hydrogel of pure alginate was developed for the targeted, short term release of SDF-1 α protein which improved healing of incisional wounds in pigs [40] and excisional wounds in mice [41]. Finally, combining these materials in a composite matrix of gelatin and oxidized alginate allowed the slow release of a cyclic adenosine monophosphate (cAMP) analog which influenced keratinocyte proliferation and migration, ultimately accelerating re-epithelialization of full-thickness wounds in rats [42, 43].

Synthetic polymers, while lacking the inherent biocompatibility of natural materials, do feature highly controllable and reproducible material properties [44]. Polyethylene glycol (PEG) is one of the most widely utilized hydrophilic polymers for drug delivery and is known for its good bio-compatibility [45]. A disulfide cross-linked PEG hydrogel was developed for the sustained release of doxycycline for wound healing. This vehicle was evaluated in an interesting mouse model of chemical warfare wounds. Skin permeation of doxycycline was enhanced by the hydrogel which correlated to better wound healing

measures [46]. PEG was also combined with another common synthetic polymer, poly(ϵ -caprolactone) (PCL), in a hydrogel for sustained release of micelles containing curcumin, a natural drug derived from the turmeric plant which has healing properties. Curcumin-delivering hydrogels successfully enhanced healing of both incisional and excisional wounds on rats [47].

Although hydrogels have been used successfully in numerous pre-clinical wound models, they do suffer one significant drawback as delivery vehicles. The nature of their formation and composition leads to a large burst release due to partial non-loading of the drug or its rapid efflux from the gel as it swells [48]. This can be particularly dangerous because systemic drug levels may become elevated and lead to unwanted side effects at distal locations. Regranex®, an FDA-approved carboxymethylcellulose hydrogel containing PDGF and indicated for diabetic ulcers, serves as an unfortunate example. A retrospective study found that it led to increased risk of cancer mortality and resulted in a black box warning issued by the FDA in 2008 [49].

SCAFFOLDS

Scaffold is a general term, so in this section we will specifically discuss porous scaffolds which are implanted rather than injected or polymerized *in situ* as is possible with hydrogels. This is usually not a drawback for wound healing applications as most wounds are superficial and relatively easy to access for manipulation. In fact, a scaffold may be the best choice when good mechanical properties or a long degradation time are desired. Their 3-D structure also encourages cell infiltration and enables strategic patterning of stimuli to precisely direct tissue regeneration [14].

Natural materials are often utilized in scaffolds similar as hydrogels, though they need not necessarily be hydrophilic. Collagen is most common and there are well-established methods for reducing its antigenicity and applying cross-links for long-term mechanical stability [50]. In one example, curcumin-incorporated collagen matrices (CICM) were developed to improve full-thickness wound healing in rats [51]. The same collagen scaffold was used to release Glycyl-histidyl-lysine (GHK), a matrikine with numerous healing properties such as angiogenesis and growth factor activation [52, 53]. Interestingly, the group has also investigated the sustained release of both reactive oxygen species (ROS) [54], and antioxidants [55] into the wound bed. FGF-2 impregnated pure gelatin sheets were also demonstrated to improve the granulation region thickness and collagen density in diabetic rat wounds [56]. These sheets also demonstrated efficacy in several patients with chronic non-healing wounds, however a randomized controlled clinical trial is necessary to conclusively assess the benefit of this therapy. An advanced wound dressing was formed from chitosan cross-linked collagen loaded with FGF-1 and demonstrated accelerated healing of diabetic rat wounds [57]. FGF-2 was also delivered by a collagen-gelatin scaffold and tested in normal wounds [58], and furthermore in a diabetic pressure ulcer model using mice [59]. In another study, the release of platelet lysate from the same scaffold was evaluated and a dose-dependent response of lysate concentration on wound healing outcomes was observed [60]. A “gene-activated” bilayer dermal equivalent (BDE) was constructed from a collagen-chitosan sponge and contained plasmid DNA encoding for

VEGF complexed with a non-viral gene delivery vector. The BDE enhanced vessel density and overall tensile strength of newly formed dermal tissue in both full-thickness excisional wounds [61] and burn wounds [62] in pigs.

Drug loading of scaffolds is often by adsorption or entrapment and is therefore poor for some non-ideal drug-scaffold combinations. One method of improving loading efficiency is by modifying the therapeutic protein itself. In one instance, VEGF was modified with a collagen-binding domain which enhanced its affinity to the endogenous ECM and retention in the granulation tissue 7 days after application to rat wounds [63]. The fusion protein was then loaded into a collagen scaffold with enhanced efficiency and greatly improved vascularization in diabetic rats, also reducing VEGF levels in the serum compared to the native protein [64]. A similar approach was used to modify neuronal growth factor (NGF) and demonstrated accelerated re-epithelialization in a rabbit ischemic ulcer model [65].

Another natural material, hyaluronic acid (HA), was used to form sponges for the sustained release of EGF and arginine, which accelerated epithelialization of diabetic rat wounds by inducing moderate inflammation in the early stage of healing [66]. Similar sponges also containing collagen were found to induce better neovascularization in a genetically type 2 diabetic mouse model compared to a commercial artificial skin [67].

Scaffolds developed using synthetic polymers often employ the fabrication technique of electrospinning. Electrospun scaffolds offer advantages of high surface area and tunable fiber diameter which may closely match those of native ECM proteins, promoting cell adhesion [68]. Core-sheath type electrospun poly(ethylene glycol)-poly(D,L-lactide) (PELA) nanofiber mats containing FGF-2 were implanted into diabetic rat wounds where they enhanced angiogenesis after 2 weeks and the scaffolds degraded completely within 4 weeks [69]. The large surface area and porosity of electrospun scaffolds allows for rapid hydrolytic degradation of polymer fibers. Similar scaffolds were also developed to provide controlled release of plasmid FGF-2. When implanted into skin defects of diabetic rats they led to improvements in numerous healing measures [70]. PEG/PCL block copolymer nanofibers have also been synthesized with chemically-immobilized EGF on their surface [71]. These scaffolds had some moderate effects on the healing of normal mouse wounds, but the results were greatly enhanced by the addition of FGF-2 within the core of co-axial fibers [72]. Likewise, curcumin has also been delivered using electrospun nanofiber mats of PEG/PCL or PCL alone, which were shown to accelerate wound healing of normal rats and diabetic mice, respectively [73, 74].

Natural polymers are often difficult to electrospin on their own and are therefore blended with synthetic polymers. One group investigated chitosan and poly(ethylene oxide) (PEO) co-electrospun with PRP as a growth factor source. The bioactivity of the proteins was demonstrated to withstand the electrospinning process with *in vitro* assays, however this therapy still requires *in vivo* validation [75]. In at least one report, chitosan scaffolds providing sustained release of EGF showed no significant benefit over unloaded scaffolds towards the healing of excisional porcine wounds [76]. These data highlight the importance of *in vivo* testing, as *in vitro* assays cannot fully recapitulate the complex environment of a wound.

Not all scaffolds are formed by electrospinning. Modified chitosan was also used to synthesize porous foam dressings for release of neurotensin (NT) to modulate the inflammatory stage in diabetic wounds. The chitosan scaffolds delivering NT increased early wound closure dramatically compared to unloaded scaffolds by mitigating the acute inflammatory response and increasing collagen deposition by dermal fibroblasts [77].

PARTICLES

Nano- and microparticles are another highly studied type of drug delivery system which hold certain advantages over hydrogels and scaffolds. With respect to wound healing applications, particles may be injected by fine-gauge needle into the healthy tissue surrounding the wound so as not to complicate healing within the wound bed. They may also be tuned through numerous parameters to have complex release profiles unobtainable with gels and scaffolds [78, 79].

Poly(lactic-co-glycolic acid) (PLGA) is the most common polymer used to synthesize particles for controlled delivery. One rationale is that the lactic acid produced as the PLGA degrades may actively participate in the healing process, stimulating collagen synthesis and angiogenesis [80]. PLGA nanoparticles were developed to protect the activity of curcumin and release it over 8 days. When evaluated in full-thickness splinted excisional wounds in mice the combined effect of lactate and curcumin reduced the inflammatory response and enhanced angiogenesis and granulation tissue formation [81]. Similar nanoparticles were also used to release EGF albeit much more quickly, lasting only a day. Still, when applied to excisional wounds in diabetic rats the therapy induced the greatest number of proliferating cells and slightly accelerated wound closure compared to free EGF solution [82].

Particles have also been developed to deliver genes or plasmids. One example are biodegradable poly(β -amino esters) (PBAE) nanoparticles used to deliver plasmid Sonic hedgehog, a morphogen known to play multiple roles in tissue regeneration. After intradermal injection of the particles at the periphery of mouse wounds, upregulation of multiple growth factors and greater neovascularization in the wounds was observed [83].

In a unique and interesting approach, nanoparticles of a silica, PEG, and chitosan composite were used to provide slow and sustained release of NO to wounds. NO is known to have both immunoregulatory and wound healing properties. The nanoparticles applied topically accelerated healing of both infected and uninfected mouse wounds [84, 85]. Furthermore they were directly compared to the common NO-donor, diethylenetriamine (DETA NONOate) and showed superior results in a mouse wound model of diabetes combined with immunodeficiency, which has significant clinical relevance [86].

Nanoparticles need not necessarily be polymeric; in fact, lipids hold an advantage of rapid self-assembly without requiring organic solvents. One group developed two types, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for delivery of EGF. The loading efficiency of NLCs was greater than that of SLNs, as is common with encapsulating cargo within a shell versus entrapping it in a matrix. Both types of lipid particles delivering EGF significantly accelerated healing of full-thickness wounds in *db/db* mice, however four

applications were necessary, possibly due to the inability of the vehicle to adequately sustain release [87].

Particles are also easily incorporated within other carrier systems to augment their functionality. They may be used to extend release if the inherent rate is too quick, or to provide biphasic release kinetics. For example, a polyurethane scaffold embedded with gelatin-coated PLGA microparticles, each releasing PDGF, produced a quick burst followed by slow prolonged release [88]. Likewise, distinct release kinetics for multiple factors will be very important for certain applications [89]. Nanofiber composite scaffolds of chitosan and PEO were synthesized for fast release of VEGF and combined with nanoparticles providing slow sustained release of PDGF. Dual release resulted in fast closure of full-thickness wounds in rats, driven by an enhanced angiogenic response [90].

In one notably elaborate delivery vehicle, VEGF and PDGF were placed in gelatin nanoparticles and combined with FGF-2 and EGF embedded in electrospun collagen and HA nanofibers for sustained release of 4 factors at once. Accelerated wound closure, increased collagen deposition and improved angiogenesis were all observed when the scaffolds were implanted in excisional wounds on diabetic rats [91]. Complex scaffolds with their own functionality have also been developed to compliment the delivery of a single factor. For example, an inner gelatin hydrogel layer for maintenance of a moist wound environment and containing FGF-2 micro-spheres was layered below an outer polyurethane membrane to protect the wound. This bi-layer scaffold proved effective at healing porcine full-thickness wounds [92].

Gelatin microparticles delivering FGF-2 suspended in a gelatin hydrogel showed good results in a porcine pressure-induced decubitus ulcer model [93]. In another approach, gelatin microspheres were conjugated to a catechol-type protease inhibitor, loaded with doxycycline, and incorporated into a collagen dressing [94]. Their ability to reduce MMP levels in the wound bed and prevent infection was evaluated in a bacteria-challenged excisional wound model in rats [95]. Finally, gelatin microparticles delivering FGF-2 were dispersed within a collagen sponge and enhanced angiogenesis and cell proliferation in a mouse model of pressure ulcers [96].

One group loaded chitosan microparticles with EGF and VEGF and suspended them in a dextran hydrogel for application to burn wounds. The therapy did show a beneficial effect in a rat burn wound model, however weekly applications were necessary, indicating that the release duration was too short [97]. Another group suspended PLGA nanoparticles delivering VEGF and FGF-2 in a composite hydrogel and applied it to full-thickness wounds on diabetic mice. This combined therapy led to improved wound closure compared to control scaffolds but not compared to the scaffold with free growth factors [98]. These results highlight some potential drawbacks of particulate delivery systems. Most require organic solvents which can reduce the bioactivity of fragile protein drugs significantly. Additionally, constant release rate is difficult to achieve because they inherently follow first-order kinetics due to changing surface area as the particles degrade [78].

COMPLEXES AND CONJUGATES

A fourth type of delivery system comprises complexes and conjugates. Conjugates are typically formed by chemical bonds while complexes are typically formed by physical interactions. Both approaches seek to sequester soluble drugs in order to stabilize and extend their half-life or to provide targeting and facilitate their interactions with cell receptors. In one of the simplest examples of conjugation, PEG was attached to FGF-1 to improve its thermal and structural stability *in vivo*. In diabetic rat wounds, PEGylated FGF-1 led to complete wound closure 4 days faster than free FGF-1 and 7 days faster than control [99]. Complexes may also be used to improve skin permeation, of interest for wounds which have formed a protective scab or to treat deep tissue injury preceding a pressure ulcer. A low molecular weight version of protamine, a cation-rich nuclear protein, was developed to complex with the N-terminus of EGF. Protamine-EGF complexes showed 11-fold greater transdermal penetration than free EGF and demonstrated efficacy in healing full-thickness wounds on both normal and diabetic mice [100] and in a mouse burn wound model [101].

Another very interesting approach involves engineering ECM mimetics, considering its significance in orchestrating the regenerative process [36, 102, 103]. One such approach is a synthetic peptide fragment of fibronectin containing its growth factor binding domain for protein loading, an in-tegrin-binding domain to localize the complex to cells, and a factor XIIIa sequence for cross-linking to form a matrix to facilitate injection. The multi-functional recombinant fibronectin was applied for co-delivery of VEGF and PDGF to diabetic mouse wounds, where it induced angiogenesis and accelerated wound closure [104]. The same group used a similar approach to deliver the cytokine CXCL11 which, synergistic with fibronectin, promoted diabetic wound healing in *db/db* mice [105]. Along similar lines, vitronectin complexes with insulin-like growth factors (IGFs) can enhance keratinocyte migration and protein synthesis [106], and similar effects were observed with EGF and FGF-2 [107]. In their first pre-clinical evaluation, vitronectin complexes of IGFs and EGF accelerated healing of partial-thickness burn wounds in pigs, although this approach did require multiple administrations per week [108]. To improve the clinical usefulness, HA was then added as a carrier system for vitronectin:GF complexes [109]. In a clinical pilot study, this therapy demonstrated convincing efficacy at re-epithelializing venous leg ulcers, and also showed promise for treating other types of chronic wounds [110]. These results provide strong evidence for consideration of the role of the ECM in growth factor signal transduction when designing controlled delivery vehicles.

Another group designed polymer-growth factor conjugates using a “Polymer Masking-UnMasking-Protein Therapy (PUMPT)”. They demonstrated that succinoylated dex- trin conjugated to EGF can stabilize the protein until the polymer degrades at the target site and “unmasks” its bioactivity [111, 112]. The group went on to evaluate dextrin-EGF in full-thickness diabetic mouse wounds and the therapy had marked success [113]. In another unique approach *S*-nitrosothiols (RNSOs) were grafted onto a polymer backbone and then interpolymer complexes were created to form a cross-linked polymer network. This vehicle provided sustained release of NO for at least 10 days and accelerated healing of excisional wounds in diabetic rats, although the mechanistic benefits were not explored [114].

The specificity of complexes and conjugates may be seen as a disadvantage because many cannot be used as a platform for delivery of different types of molecules. Because they are designed with a specific target in mind, the synthesis and optimization process can become time-consuming. On the other hand, a specialized delivery vehicle will often lead to better outcomes compared to delivery with a generalized release platform.

COACERVATES

Coacervates are an interesting new class of drug delivery vehicles developed only recently for controlled release of proteins and small molecule drugs. Coacervates are nanometer-sized liquid droplets, held together and apart from their environment by hydrophobic forces [115]. As delivery vehicles, they feature rapid preparation by self-assembly not requiring organic solvents, and high loading capacity [116]. Preparation in aqueous solution is convenient and circumvents the risk of protein denaturation or residual organic solvents in conventional particle synthesis. Coacervates are also distinct from polymeric particles in their mechanical properties; they are soft and deformable which is particularly amenable to a wound environment where they may reside without impeding the massive influx of cells. This deformable nature allows for quick adsorption and spreading to coat polymeric scaffolds and provide drug release for tissue engineering applications [117]. Although they are a relatively young technology with just a decade's worth of experimental validation, the advantages several coacervate systems have shown over conventional delivery methods bears much promise for their utility in the future [118].

One well-described coacervate system is elastin-like peptides (ELPs). These are recombinant proteins which resemble the hydrophobic regions of tropoelastin which undergo spontaneous coacervation above a tunable transition temperature [119]. Fusion proteins containing ELPs and KGF were developed and self-assembled into coacervate particles at body temperature. A chronic wound model was performed using an insulin-resistant diabetic mouse strain, and the fusion peptide led to markedly enhanced granulation and re-epithelialization [120].

A second coacervate system is a polycation:heparin complex which was developed specifically for the controlled delivery of heparin-binding growth factors [121, 122]. The growth factor is pre-bound to heparin, then a synthetic poly-cation is added which instantly forms liquid coacervate droplets by charge-based complexation (Fig. 2A). Within the coacervate the growth factor is protected from the proteolytic wound environment and its bioactivity upon release is enhanced by heparan sulfate proteoglycan-like interactions. This coacervate was utilized to sustain the release of heparin-binding epidermal growth factor (HB-EGF) with near zero-order release kinetics for at least 10 days. A single application of the HB-EGF coacervate to full-thickness excisional mouse wounds accelerated wound closure by enhancing wound granulation, re-epithelialization, keratinocyte proliferation, and angiogenesis (Fig. 2B) [123].

One drawback of coacervates is their relative instability in the body. They are held together by relatively weak interactions which may dissociate by large environmental changes in pH or ionic strength. However, these are typically stable within a particular tissue in the body.

On the other hand, this responsiveness may also be used to build in stimuli-responsive specificity.

CONCLUSION

A wide variety of biomaterial-based delivery systems exist for proteins, genes, and small molecule drugs with wound healing applications. Hydrogels, scaffolds, particles, complexes, and coacervates have each demonstrated success in numerous *in vivo* models and each may be optimal for a particular application or circumstance. However, wound healing is an extremely complex process and it is important to understand the etiology of each wound type and develop similarly complex delivery systems for individualized treatment. Towards this goal, it will be necessary to combine different types of biomaterials to develop composite systems capable of delivering multiple factors with precise release kinetics.

Acknowledgments

The authors would like to thank Dr. Mantosh Sinha for providing the hydrogel image, Dr. Eric Jeffries for providing the electrospun scaffold image, and Mr. Andrew Glowacki for providing the microparticles image. This work was supported by grants from the National Institutes of Health (NIH 2T32HL076124), the National Science Foundation (NSF IIP-1444774), and the American Heart Association (12EIA9020016).

Biography

Yadong Wang

References

1. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. *J Clin Invest.* 2007; 117(5):1219–1222. [PubMed: 17476353]
2. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. *Wound Repair Regen.* 2008; 16(5):585–601. [PubMed: 19128254]
3. Singer AJ, Clark RA. Cutaneous wound healing. *New Engl J Med.* 1999; 341(10):738–746. [PubMed: 10471461]
4. Behm B, Babilas P, Landthaler M, Schreml S. Cytokines, chemokines and growth factors in wound healing. *J Eur Acad Dermatol Venereol.* 2011
5. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. *Physiol Rev.* 2003; 83(3):835–870. [PubMed: 12843410]
6. Boateng JS, Matthews KH, Stevens HN, Eccleston GM. Wound healing dressings and drug delivery systems: A review. *J Pharm Sci.* 2008; 97(8):2892–2923. [PubMed: 17963217]
7. Koria P. Delivery of growth factors for tissue regeneration and wound healing. *BioDrugs.* 2012; 26(3):163–175. [PubMed: 22500904]
8. Katti DS, Robinson KW, Ko FK, Laurencin CT. Bioresorbable nanofiber-based systems for wound healing and drug delivery: Optimization of fabrication parameters. *J Biomed Mater Res B.* 2004; 70(2):286–296.

9. Branski LK, Pereira CT, Herndon DN, Jeschke MG. Gene therapy in wound healing: present status and future directions. *Gene Ther.* 2007; 14(1):1–10. [PubMed: 16929353]
10. Hirsch T, Spielmann M, Yao F, Eriksson E. Gene therapy in cutaneous wound healing. *Front Biosci.* 2007; 12:2507–2518. [PubMed: 17127259]
11. Greer N, Foman N, Wilt T, Dorrian J, Fitzgerald P, MacDonald R, Rutks I. Advanced Wound care therapies for non-healing diabetic, venous, and arterial ulcers: A systematic review. 2012
12. Clark RA, Ghosh K, Tonnesen MG. Tissue engineering for cutaneous wounds. *J Invest Dermatol.* 2007; 127(5):1018–1029. [PubMed: 17435787]
13. Kamel RA, Ong JF, Eriksson E, Junker JP, Caterson EJ. Tissue engineering of skin. *J Am Coll Surg.* 2013; 217(3):533–555. [PubMed: 23816384]
14. Drury JL, Mooney DJ. Hydrogels for tissue engineering: scaffold design variables and applications. *Biomaterials.* 2003; 24(24):4337–4351. [PubMed: 12922147]
15. Ueno H, Mori T, Fujinaga T. Topical formulations and wound healing applications of chitosan. *Adv Drug Deliv Rev.* 2001; 52(2):105–115. [PubMed: 11718934]
16. Mi FL, Wu YB, Shyu SS, Chao AC, Lai JY, Su CC. Asymmetric chitosan membranes prepared by dry/wet phase separation: a new type of wound dressing for controlled antibacterial release. *J Membrane Sci.* 2003; 212(1-2):237–254.
17. Mi FL, Wu YB, Shyu SS, Schoung JY, Huang YB, Tsai YH, Hao JY. Control of wound infections using a bilayer chitosan wound dressing with sustainable antibiotic delivery. *J Biomed Mater Res.* 2002; 59(3):438–449. [PubMed: 11774301]
18. Meng X, Tian F, Yang J, He CN, Xing N, Li F. Chitosan and alginate polyelectrolyte complex membranes and their properties for wound dressing application. *J Mater Sci Mater Med.* 2010; 21(5):1751–1759. [PubMed: 20101440]
19. Noel SP, Courtney H, Bumgardner JD, Haggard WO. Chitosan films: a potential local drug delivery system for antibiotics. *Clin Orthop Relat Res.* 2008; 466(6):1377–1382. [PubMed: 18421540]
20. Smith JK, Bumgardner JD, Courtney HS, Smeltzer MS, Haggard WO. Antibiotic-loaded chitosan film for infection prevention: A preliminary in vitro characterization. *J Biomed Mater Res B.* 2010; 94(1):203–211.
21. Jackson SR, Richelsoph KC, Courtney HS, Wenke JC, Branstetter JG, Bumgardner JD, Haggard WO. Preliminary in vitro evaluation of an adjunctive therapy for extremity wound infection reduction: rapidly resorbing local antibiotic delivery. *J Orthop Res.* 2009; 27(7):903–908. [PubMed: 19105225]
22. Smith JK, Moshref AR, Jennings JA, Courtney HS, Haggard WO. Chitosan sponges for local synergistic infection therapy: a pilot study. *Clin Orthop Relat Res.* 2013; 471(10):3158–3164. [PubMed: 23604649]
23. Stinner DJ, Noel SP, Haggard WO, Watson JT, Wenke JC. Local antibiotic delivery using tailorable chitosan sponges: the future of infection control. *J Orthop Trauma.* 2010; 24(9):592–597. [PubMed: 20736801]
24. Mizuno K, Yamamura K, Yano K, Osada T, Saeki S, Takimoto N, Sakurai T, Nimura Y. Effect of chitosan film containing basic fibroblast growth factor on wound healing in genetically diabetic mice. *J Biomed Mater Res A.* 2003; 64(1):177–181. [PubMed: 12483711]
25. Ishihara M, Fujita M, Obara K, Hattori H, Nakamura S, Nambu M, Kiyosawa T, Kanatani Y, Takase B, Kikuchi M, Maehara T. Controlled releases of FGF-2 and paclitaxel from chitosan hydrogels and their subsequent effects on wound repair, angiogenesis, and tumor growth. *Curr Drug Deliv.* 2006; 3(4):351–358. [PubMed: 17076636]
26. Tran NQ, Joung YK, Lih E, Park KD. In situ forming and rutin-releasing chitosan hydrogels as injectable dressings for dermal wound healing. *Biomacromolecules.* 2011; 12(8):2872–2880. [PubMed: 21591793]
27. Obara K, Ishihara M, Ishizuka T, Fujita M, Ozeki Y, Maehara T, Saito Y, Yura H, Matsui T, Hattori H, Kikuchi M, Kurita A. Photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 stimulates wound healing in healing-impaired db/db mice. *Biomaterials.* 2003; 24(20):3437–3444. [PubMed: 12809772]

28. Breen A, O'Brien T, Pandit A. Fibrin as a delivery system for therapeutic drugs and biomolecules. *Tissue Eng Part B Rev*. 2009; 15(2):201–214. [PubMed: 19249942]
29. Trentin D, Hall H, Wechsler S, Hubbell JA. Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1 α variant for local induction of angiogenesis. *Proc Natl Acad Sci USA*. 2006; 103(8):2506–2511. [PubMed: 16477043]
30. Breen AM, Dockery P, O'Brien T, Pandit AS. The use of therapeutic gene eNOS delivered via a fibrin scaffold enhances wound healing in a compromised wound model. *Biomaterials*. 2008; 29(21):3143–3151. [PubMed: 18442851]
31. Breen A, Dockery P, O'Brien T, Pandit A. Fibrin scaffold promotes adenoviral gene transfer and controlled vector delivery. *J Biomed Mater Res A*. 2009; 89(4):876–884. [PubMed: 18465822]
32. Kulkarni M, O'Loughlin A, Vazquez R, Mashayekhi K, Rooney P, Greiser U, O'Toole E, O'Brien T, Malagon MM, Pandit A. Use of a fibrin-based system for enhancing angiogenesis and modulating inflammation in the treatment of hyperglycemic wounds. *Biomaterials*. 2014; 35(6):2001–2010. [PubMed: 24331702]
33. Geer DJ, Swartz DD, Andreadis ST. Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing *in vitro* and *in vivo*. *Am J Pathol*. 2005; 167(6):1575–1586. [PubMed: 16314471]
34. Pandit AS, Wilson DJ, Feldman DS. Fibrin scaffold as an effective vehicle for the delivery of acidic fibroblast growth factor (FGF-1). *J Biomater Appl*. 2000; 14(3):229–242. [PubMed: 10656542]
35. Pandit AS, Feldman DS, Caulfield J, Thompson A. Stimulation of angiogenesis by FGF-1 delivered through a modified fibrin scaffold. *Growth Factors*. 1998; 15(2):113–123. [PubMed: 9505167]
36. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. *Nat Biotechnol*. 2005; 23(1):47–55. [PubMed: 15637621]
37. Yang HS, Shin J, Bhang SH, Shin JY, Park J, Im GI, Kim CS, Kim BS. Enhanced skin wound healing by a sustained release of growth factors contained in platelet-rich plasma. *Exp Mol Med*. 2011; 43(11):622–629. [PubMed: 21847007]
38. Liu Y, Cai S, Shu XZ, Shelby J, Prestwich GD. Release of basic fibroblast growth factor from a crosslinked glycosaminoglycan hydrogel promotes wound healing. *Wound Repair Regen*. 2007; 15(2):245–251. [PubMed: 17352757]
39. Hong SR, Lee SJ, Shim JW, Choi YS, Lee YM, Song KW, Park MH, Nam YS, Lee SI. Study on gelatin-containing artificial skin IV: A comparative study on the effect of antibiotic and EGF on cell proliferation during epidermal healing. *Biomaterials*. 2001; 22(20):2777–2783. [PubMed: 11545312]
40. Rabbany SY, Pastore J, Yamamoto M, Miller T, Rafii S, Aras R, Penn M. Continuous delivery of stromal cell-derived factor-1 from alginate scaffolds accelerates wound healing. *Cell Transplant*. 2010; 19(4):399–408. [PubMed: 19995484]
41. Henderson PW, Singh SP, Krijgh DD, Yamamoto M, Rafii DC, Sung JJ, Rafii S, Rabbany SY, Spector JA. Stromal-derived factor-1 delivered via hydrogel drug-delivery vehicle accelerates wound healing *in vivo*. *Wound Repair Regen*. 2011; 19(3):420–425. [PubMed: 21518091]
42. Balakrishnan B, Mohanty M, Umashankar PR, Jayakrishnan A. Evaluation of an in situ forming hydrogel wound dressing based on oxidized alginate and gelatin. *Biomaterials*. 2005; 26(32):6335–6342. [PubMed: 15919113]
43. Balakrishnan B, Mohanty M, Fernandez AC, Mohanan PV, Jayakrishnan A. Evaluation of the effect of incorporation of dibutyl cyclic adenosine monophosphate in an in situ-forming hydrogel wound dressing based on oxidized alginate and gelatin. *Biomaterials*. 2006; 27(8):1355–1361. [PubMed: 16146648]
44. Sokolsky-Papkov M, Agashi K, Olaye A, Shakesheff K, Domb AJ. Polymer carriers for drug delivery in tissue engineering. *Adv Drug Deliv Rev*. 2007; 59(4-5):187–206. [PubMed: 17540473]
45. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. *Ange Chemie*. 2010; 49(36):6288–6308.

46. Anumolu SS, Menjoge AR, Deshmukh M, Gerecke D, Stein S, Laskin J, Sinko PJ. Doxycycline hydrogels with reversible disulfide crosslinks for dermal wound healing of mustard injuries. *Biomaterials*. 2011; 32(4):1204–1217. [PubMed: 20950853]
47. Gong C, Wu Q, Wang Y, Zhang D, Luo F, Zhao X, Wei Y, Qian Z. A biodegradable hydrogel system containing curcumin encapsulated in micelles for cutaneous wound healing. *Biomaterials*. 2013; 34(27):6377–6387. [PubMed: 23726229]
48. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. *J Control Release*. 2001; 73(2-3):121–136. [PubMed: 11516493]
49. FDA Update of Safety Review: Follow-up to the March 27, 2008 Communication about the Ongoing Safety Review of Regranex (becaplermin) Health and Human Services; 2008
50. Glowacki J, Mizuno S. Collagen scaffolds for tissue engineering. *Biopolymers*. 2008; 89(5):338–344. [PubMed: 17941007]
51. Gopinath D, Ahmed MR, Gomathi K, Chitra K, Sehgal PK, Jayakumar R. Dermal wound healing processes with curcumin incorporated collagen films. *Biomaterials*. 2004; 25(10):1911–1917. [PubMed: 14738855]
52. Arul V, Kartha R, Jayakumar R. A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. *Life Sci*. 2007; 80(4):275–284. [PubMed: 17049946]
53. Arul V, Gopinath D, Gomathi K, Jayakumar R. Biotinylated GHK peptide incorporated collagenous matrix: A novel biomaterial for dermal wound healing in rats. *J Biomed Mater Res B*. 2005; 73(2):383–391.
54. Arul V, Masilamoni JG, Jesudason EP, Jaji PJ, Inayathullah M, Dicky John DG, Vignesh S, Jayakumar R. Glucose oxidase incorporated collagen matrices for dermal wound repair in diabetic rat models: a biochemical study. *J Biomater Appl*. 2012; 26(8):917–938. [PubMed: 21363874]
55. Gomathi K, Gopinath D, Rafiuddin Ahmed M, Jayakumar R. Quercetin incorporated collagen matrices for dermal wound healing processes in rat. *Biomaterials*. 2003; 24(16):2767–2772. [PubMed: 12711523]
56. Matsumoto S, Tanaka R, Okada K, Arita K, Hyakusoku H, Miyamoto M, Tabata Y, Mizuno H. The effect of control-released basic fibroblast growth factor in wound healing: Histological analyses and clinical application. *Plast Reconstr Surg*. 2013; 1(6):e44.doi: 10.1097/GOX.0b013e3182a88787
57. Wang W, Lin S, Xiao Y, Huang Y, Tan Y, Cai L, Li X. Acceleration of diabetic wound healing with chitosan-crosslinked collagen sponge containing recombinant human acidic fibroblast growth factor in healing-impaired STZ diabetic rats. *Life Sci*. 2008; 82(3-4):190–204. [PubMed: 18164317]
58. Kanda N, Morimoto N, Takemoto S, Ayvazyan AA, Kawai K, Sakamoto Y, Taira T, Suzuki S. Efficacy of novel collagen/gelatin scaffold with sustained release of basic fibroblast growth factor for dermis-like tissue regeneration. *Ann Plast Surg*. 2012; 69(5):569–574. [PubMed: 21734552]
59. Kanda N, Morimoto N, Ayvazyan AA, Takemoto S, Kawai K, Nakamura Y, Sakamoto Y, Taira T, Suzuki S. Evaluation of a novel collagen-gelatin scaffold for achieving the sustained release of basic fibroblast growth factor in a diabetic mouse model. *J Tissue Eng Regen Med*. 2014; 8(1):29–40. [PubMed: 22628359]
60. Ito R, Morimoto N, Pham LH, Taira T, Kawai K, Suzuki S. Efficacy of the controlled release of concentrated platelet lysate from a collagen/gelatin scaffold for dermis-like tissue regeneration. *Tissue Eng Part A*. 2013; 19(11-12):1398–1405. [PubMed: 23427847]
61. Guo R, Xu S, Ma L, Huang A, Gao C. Enhanced angiogenesis of gene-activated dermal equivalent for treatment of full thickness incisional wounds in a porcine model. *Biomaterials*. 2010; 31(28):7308–20. [PubMed: 20598366]
62. Guo R, Xu S, Ma L, Huang A, Gao C. The healing of full-thickness burns treated by using plasmid DNA encoding VEGF-165 activated collagen-chitosan dermal equivalents. *Biomaterials*. 2011; 32(4):1019–1031. [PubMed: 21071076]
63. Yan X, Chen B, Lin Y, Li Y, Xiao Z, Hou X, Tan Q, Dai J. Acceleration of diabetic wound healing by collagen-binding vascular endothelial growth factor in diabetic rat model. *Diabetes Res Clin Pract*. 2010; 90(1):66–72. [PubMed: 20667614]

64. Tan Q, Chen B, Yan X, Lin Y, Xiao Z, Hou X, Dai J. Promotion of diabetic wound healing by collagen scaffold with collagen-binding vascular endothelial growth factor in a diabetic rat model. *J Tissue Eng Regen Med*. 2014; 8(3):195–201. [PubMed: 22570298]
65. Sun W, Lin H, Chen B, Zhao W, Zhao Y, Xiao Z, Dai J. Collagen scaffolds loaded with collagen-binding NGF-beta accelerate ulcer healing. *J Biomed Mater Res A*. 2010; 92(3):887–895. [PubMed: 19283824]
66. Matsumoto Y, Kuroyanagi Y. Development of a wound dressing composed of hyaluronic acid sponge containing arginine and epidermal growth factor. *J Biomater Sci Polym Ed*. 2010; 21(6): 715–726. [PubMed: 20482980]
67. Kondo S, Kuroyanagi Y. Development of a wound dressing composed of hyaluronic acid and collagen sponge with epidermal growth factor. *J Biomater Sci Polym Ed*. 2012; 23(5):629–643. [PubMed: 21375805]
68. Sill TJ, von Recum HA. Electrospinning: Applications in drug delivery and tissue engineering. *Biomaterials*. 2008; 29(13):1989–2006. [PubMed: 18281090]
69. Yang Y, Xia T, Zhi W, Wei L, Weng J, Zhang C, Li X. Promotion of skin regeneration in diabetic rats by electrospun core-sheath fibers loaded with basic fibroblast growth factor. *Biomaterials*. 2011; 32(18):4243–4254. [PubMed: 21402405]
70. Yang Y, Xia T, Chen F, Wei W, Liu C, He S, Li X. Electrospun fibers with plasmid bFGF polyplex loadings promote skin wound healing in diabetic rats. *Mol Pharm*. 2012; 9(1):48–58. [PubMed: 22091745]
71. Choi JS, Leong KW, Yoo HS. In vivo wound healing of diabetic ulcers using electrospun nanofibers immobilized with human epidermal growth factor (EGF). *Biomaterials*. 2008; 29(5): 587–596. [PubMed: 17997153]
72. Choi JS, Choi SH, Yoo HS. Coaxial electrospun nanofibers for treatment of diabetic ulcers with binary release of multiple growth factors. *J Mater Chem*. 2011; 21:5258–5267.
73. Fu SZ, Meng XH, Fan J, Yang LL, Wen QL, Ye SJ, Lin S, Wang BQ, Chen LL, Wu JB, Chen Y, Fan JM, Li Z. Acceleration of dermal wound healing by using electrospun curcumin-loaded poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) fibrous mats. *J Biomed Mater Res B*. 2014; 102(3):533–542.
74. Merrell JG, McLaughlin SW, Tie L, Laurencin CT, Chen AF, Nair LS. Curcumin-loaded poly(epsilon-caprolactone) nanofibres: Diabetic wound dressing with anti-oxidant and anti-inflammatory properties. *Clin Exp Pharmacol Physiol*. 2009; 36(12):1149–1156. [PubMed: 19473187]
75. Bertoncelj V, Pelipenko J, Kristl J, Jeras M, Cukjati M, Kocbek P. Development and bioevaluation of nanofibers with blood-derived growth factors for dermal wound healing. *Eur J Pharm Biopharm*. 2014; (0)
76. Hong JP, Kim YW, Lee SK, Kim SH, Min KH. The effect of continuous release of recombinant human epidermal growth factor (rh-EGF) in chitosan film on full thickness excisional porcine wounds. *Ann Plast Surg*. 2008; 61(4):457–462. [PubMed: 18812721]
77. Moura LI, Dias AM, Leal EC, Carvalho L, de Sousa HC, Carvalho E. Chitosan-based dressings loaded with neurotensin—an efficient strategy to improve early diabetic wound healing. *Acta Biomater*. 2014; 10(2):843–57. [PubMed: 24121197]
78. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. *J Control Release*. 2001; 70(1-2):1–20. [PubMed: 11166403]
79. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. *Colloid Surface B*. 2010; 75(1):1–18.
80. Porporato PE, Payen VL, De Saedeleer CJ, Preat V, Thissen JP, Feron O, Sonveaux P. Lactate stimulates angiogenesis and accelerates the healing of superficial and ischemic wounds in mice. *Angiogenesis*. 2012; 15(4):581–592. [PubMed: 22660894]
81. Cherreddy KK, Coco R, Memvanga PB, Ucakar B, des Rieux A, Vandermeulen G, Preat V. Combined effect of PLGA and curcumin on wound healing activity. *J Control Release*. 2013; 171(2):208–215. [PubMed: 23891622]

82. Chu Y, Yu D, Wang P, Xu J, Li D, Ding M. Nanotechnology promotes the full-thickness diabetic wound healing effect of recombinant human epidermal growth factor in diabetic rats. *Wound Repair Regen.* 2010; 18(5):499–505. [PubMed: 20840519]
83. Park HJ, Lee J, Kim MJ, Kang TJ, Jeong Y, Um SH, Cho SW. Sonic hedgehog intradermal gene therapy using a biodegradable poly(beta-amino esters) nanoparticle to enhance wound healing. *Biomaterials.* 2012; 33(35):9148–9156. [PubMed: 23018131]
84. Han G, Nguyen LN, Macherla C, Chi Y, Friedman JM, Nosanchuk JD, Martinez LR. Nitric oxide-releasing nanoparticles accelerate wound healing by promoting fibroblast migration and collagen deposition. *Am J Pathol.* 2012; 180(4):1465–1473. [PubMed: 22306734]
85. Martinez LR, Han G, Chacko M, Mihu MR, Jacobson M, Gialanella P, Friedman AJ, Nosanchuk JD, Friedman JM. Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against *Staphylococcus aureus* skin infection. *J Invest Dermatol.* 2009; 129(10):2463–2469. [PubMed: 19387479]
86. Blecher K, Martinez LR, Tuckman-Vernon C, Nacharaju P, Schairer D, Chouake J, Friedman JM, Alfieri A, Guha C, Nosanchuk JD, Friedman AJ. Nitric oxide-releasing nanoparticles accelerate wound healing in NOD-SCID mice. *Nanomedicine.* 2012; 8(8):1364–1371. [PubMed: 22406184]
87. Gainza G, Pastor M, Aguirre JJ, Villullas S, Pedraz JL, Hernandez RM, Igartua M. A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: In vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice. *J Control Release.* 2014; 185:51–61. [PubMed: 24794895]
88. Li B, Davidson JM, Guelcher SA. The effect of the local delivery of platelet-derived growth factor from reactive two-component polyurethane scaffolds on the healing in rat skin excisional wounds. *Biomaterials.* 2009; 30(20):3486–3494. [PubMed: 19328544]
89. Chen FM, Zhang M, Wu ZF. Toward delivery of multiple growth factors in tissue engineering. *Biomaterials.* 2010; 31(24):6279–6308. [PubMed: 20493521]
90. Xie Z, Paras CB, Weng H, Punnakitakashem P, Su LC, Vu K, Tang L, Yang J, Nguyen KT. Dual growth factor releasing multi-functional nanofibers for wound healing. *Acta Biomater.* 2013; 9(12):9351–9359. [PubMed: 23917148]
91. Lai HJ, Kuan CH, Wu HC, Tsai JC, Chen TM, Hsieh DJ, Wang TW. Tailored design of electrospun composite nanofibers with staged release of multiple angiogenic growth factors for chronic wound healing. *Acta Biomater.* 2014
92. Huang S, Deng T, Wu H, Chen F, Jin Y. Wound dressings containing bFGF-impregnated microspheres. *J Microencapsul.* 2006; 23(3):277–290. [PubMed: 16801240]
93. Jiang W, Wang H, Jin F, Yu C, Chu D, Wang L, Lu X. Improved wound healing in pressure-induced decubitus ulcer with controlled release of basic fibroblast growth factor. *J Alloy Compd.* 2008; 459(1-2):508–514.
94. Adhirajan N, Shanmugasundaram N, Shanmuganathan S, Babu M. Functionally modified gelatin microspheres impregnated collagen scaffold as novel wound dressing to attenuate the proteases and bacterial growth. *Eur J Pharm Sci.* 2009; 36(2-3):235–245. [PubMed: 18952165]
95. Adhirajan N, Shanmugasundaram N, Shanmuganathan S, Babu M. Collagen-based wound dressing for doxycycline delivery: In-vivo evaluation in an infected excisional wound model in rats. *J Pharm Pharmacol.* 2009; 61(12):1617–1623. [PubMed: 19958583]
96. Kawai K, Suzuki S, Tabata Y, Nishimura Y. Accelerated wound healing through the incorporation of basic fibroblast growth factor-impregnated gelatin microspheres into artificial dermis using a pressure-induced decubitus ulcer model in genetically diabetic mice. *Br J Plast Surg.* 2005; 58(8):1115–1123. [PubMed: 15950956]
97. Ribeiro MP, Morgado PI, Miguel SP, Coutinho P, Correia IJ. Dextran-based hydrogel containing chitosan microparticles loaded with growth factors to be used in wound healing. *Mater Sci Eng C.* 2013; 33(5):2958–2966.
98. Losi P, Briganti E, Errico C, Lisella A, Sanguinetti E, Chiellini F, Soldani G. Fibrin-based scaffold incorporating VEGF- and bFGF-loaded nanoparticles stimulates wound healing in diabetic mice. *Acta Biomater.* 2013; 9(8):7814–7821. [PubMed: 23603001]

99. Huang Z, Lu M, Zhu G, Gao H, Xie L, Zhang X, Ye C, Wang Y, Sun C, Li X. Acceleration of diabetic-wound healing with PEGylated rhaFGF in healing-impaired streptozocin diabetic rats. *Wound Repair Regen.* 2011; 19(5):633–644. [PubMed: 22092801]
100. Choi JK, Jang JH, Jang WH, Kim J, Bae IH, Bae J, Park YH, Kim BJ, Lim KM, Park JW. The effect of epidermal growth factor (EGF) conjugated with low-molecular-weight protamine (LMWP) on wound healing of the skin. *Biomaterials.* 2012; 33(33):8579–8790. [PubMed: 22910220]
101. Lee JH, Bae IH, Choi JK, Park JW. Evaluation of a highly skin permeable low-molecular-weight protamine conjugated epidermal growth factor for novel burn wound healing therapy. *J Pharm Sci.* 2013; 102(11):4109–4120. [PubMed: 24018779]
102. Uebersax L, Merkle HP, Meinel L. Biopolymer-based growth factor delivery for tissue repair: from natural concepts to engineered systems. *Tissue Eng Part B Rev.* 2009; 15(3):263–289. [PubMed: 19416020]
103. Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. *Wound Repair Regen.* 2009; 17(2):153–162. [PubMed: 19320882]
104. Martino MM, Tortelli F, Mochizuki M, Traub S, Ben-David D, Kuhn GA, Muller R, Livne E, Eming SA, Hubbell JA. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. *Sci Transl Med.* 2011; 3(100):100ra89.
105. Tortelli F, Pisano M, Briquez PS, Martino MM, Hubbell JA. Fibronectin binding modulates CXCL11 activity and facilitates wound healing. *PLoS One.* 2013; 8(10):e79610. [PubMed: 24205388]
106. Hyde C, Hollier B, Anderson A, Harkin D, Upton Z. Insulin-like growth factors (IGF) and IGF-binding proteins bound to vitronectin enhance keratinocyte protein synthesis and migration. *J Invest Dermatol.* 2004; 122(5):1198–206. [PubMed: 15140223]
107. Hollier B, Harkin DG, Leavesley D, Upton Z. Responses of keratinocytes to substrate-bound vitronectin: Growth factor complexes. *Exp Cell Res.* 2005; 305(1):221–232. [PubMed: 15777802]
108. Upton Z, Cuttle L, Noble A, Kempf M, Topping G, Malda J, Xie Y, Mill J, Harkin DG, Kravchuk O, Leavesley DI, Kimble RM. Vitronectin: Growth factor complexes hold potential as a wound therapy approach. *J Invest Dermatol.* 2008; 128(6):1535–1544. [PubMed: 18200066]
109. Xie Y, Upton Z, Richards S, Rizzi SC, Leavesley DI. Hyaluronic acid: Evaluation as a potential delivery vehicle for vitronectin: growth factor complexes in wound healing applications. *J Control Release.* 2011
110. Upton Z, Wallace HJ, Shooter GK, van Lonkhuyzen DR, Yeoh-Ellerton S, Rayment EA, Fleming JM, Broszczak D, Queen D, Sibbald RG, Leavesley DI, Stacey MC. Human pilot studies reveal the potential of a vitronectin: Growth factor complex as a treatment for chronic wounds. *Int Wound J.* 2011; 8(5):522–532. [PubMed: 21914133]
111. Hardwicke J, Ferguson EL, Moseley R, Stephens P, Thomas DW, Duncan R. Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair. *J Control Release.* 2008; 130(3): 275–83. [PubMed: 18700156]
112. Hardwicke J, Moseley R, Stephens P, Harding K, Duncan R, Thomas DW. Bioresponsive dextrin-rhEGF conjugates: In vitro evaluation in models relevant to its proposed use as a treatment for chronic wounds. *Mol Pharm.* 2010; 7(3):699–707. [PubMed: 20166755]
113. Hardwicke JT, Hart J, Bell A, Duncan R, Thomas DW, Moseley R. The effect of dextrin-rhEGF on the healing of full-thickness, excisional wounds in the (db/db) diabetic mouse. *J Control Release.* 2011; 152(3):411–417. [PubMed: 21435363]
114. Li Y, Lee PI. Controlled nitric oxide delivery platform based on S-nitrosothiol conjugated interpolymer complexes for diabetic wound healing. *Mol Pharm.* 2010; 7(1):254–66. [PubMed: 20030413]
115. Overbeek JTG, Voorn MJ. Phase separation in polyelectrolyte solutions. Theory of complex coacervation. *J Cell Compar Physl.* 1957; 49(S1):7–26.
116. De Kruif CG, Weinbreck F, De Vries R. Complex coacervation of proteins and anionic polysaccharides. *Curr Opin Colloid In.* 2004; 9(5):340–349.

117. Lee KW, Johnson NR, Gao J, Wang Y. Human progenitor cell recruitment via SDF-1 α coacervate-laden PGS vascular grafts. *Biomaterials*. 2013; 34(38):9877–9885. [PubMed: 24060423]
118. Johnson NR, Wang Y. Coacervate delivery systems for proteins and small molecule drugs. *Expert Opin Drug Deliv*. 2014:1–4.
119. MacEwan SR, Chilkoti A. Elastin-like polypeptides: biomedical applications of tunable biopolymers. *Biopolymers*. 2010; 94(1):60–77. [PubMed: 20091871]
120. Koria P, Yagi H, Kitagawa Y, Megeed Z, Nahmias Y, Sheridan R, Yarmush ML. Self-assembling elastin-like peptides growth factor chimeric nanoparticles for the treatment of chronic wounds. *Proc Natl Acad Sci USA*. 2011; 108(3):1034–1039. [PubMed: 21193639]
121. Chu H, Johnson NR, Mason NS, Wang Y. A [polycation:heparin] complex releases growth factors with enhanced bioactivity. *J Control Release*. 2011; 150(2):157–163. [PubMed: 21118705]
122. Johnson NR, Ambe T, Wang Y. Lysine-based polycation: Heparin coacervate for controlled protein delivery. *Acta Biomater*. 2014; 10(1):40–46. [PubMed: 24075887]
123. Johnson NR, Wang Y. Controlled delivery of heparin-binding EGF-like growth factor yields fast and comprehensive wound healing. *J Control Release*. 2013; 166(2):124–129. [PubMed: 23154193]

Fig. 1.
Five types of delivery systems.

Fig. 2.

(A) A polycation:heparin coacervate forms by charge interaction and loads heparin-binding growth factors. (B) The HB-EGF coacervate was evaluated in a mouse skin wound healing model.